Dr.Β CarlΒ June
MD, Board-Certified in Internal Medicine and Medical Oncology
Richard W. Vague Professor in Immunotherapy
corporate_fareUniversity of Pennsylvania / Penn Medicine, Philadelphia
Carl June
MD, Board-Certified in Internal Medicine and Medical Oncology
Dr. Carl H. June, MD, is a physician-scientist at the University of Pennsylvania and Penn Medicine who is internationally recognised for pioneering CAR-T cell therapy. He is the Richard W. Vague Professor in Immunotherapy in the Department of Pathology and Laboratory Medicine.
Dr. June directs the Center for Cellular Immunotherapies at the Perelman School of Medicine and the Parker Institute for Cancer Immunotherapy at the University of Pennsylvania. In 2011, his research team reported treating patients with relapsed or refractory chronic lymphocytic leukaemia using genetically engineered versions of their own T cells, work that helped lead to tisagenlecleucel (Kymriah), approved by the FDA in 2017 as the first personalised cellular therapy for certain leukaemia and lymphoma patients. He was awarded the 2024 Breakthrough Prize in Life Sciences for the development of CAR-T cell immunotherapy and has authored more than 500 peer-reviewed manuscripts. His laboratory continues to study lymphocyte biology, ex vivo T-cell engineering, and adoptive immunotherapy for cancer.
CancerFax can help international patients and families organise medical records and explore CAR-T cell therapy pathways at Penn Medicine's cellular therapy programmes. Final eligibility and treatment decisions are made by the treating institution.
Why Dr. Carl June Is Important in CAR-T Therapy
Dr. June is one of the most recognised physician-scientists in cellular immunotherapy, and his work underpins the CAR-T treatments many blood cancer patients ask about today.
Areas of Specialisation
Engineered T-cell and cellular immunotherapy for blood cancers
CAR-T & Engineered T-Cell Therapy
Genetically engineered T-cell approaches developed and studied in Dr. June's programme.
- arrow_rightCTL019 / tisagenlecleucel (Kymriah) research and development
- arrow_rightEngineered T cells for relapsed or refractory B-cell malignancies
- arrow_rightEx vivo T-cell engineering and manufacturing
- arrow_rightDevelopment of new chimeric antigen receptors and vectors
Cellular Immunotherapy for Blood Cancers
Adoptive cell therapy approaches for leukaemia, lymphoma, and related malignancies.
- arrow_rightRelapsed or refractory chronic lymphocytic leukaemia (CLL)
- arrow_rightB-cell acute lymphoblastic leukaemia and B-cell non-Hodgkin lymphoma
- arrow_rightLymphocyte biology and immune tolerance
- arrow_rightTranslational cellular therapy from laboratory to clinic
Clinical & Research Focus
Cellular therapy programme leadership and translational research
Dr. June is a physician-scientist whose work centres on developing and translating engineered T-cell therapies. Clinical CAR-T evaluation and treatment at Penn Medicine are delivered by the Abramson Cancer Center cellular therapy team.
Cellular Therapy Programme Direction
MultidisciplinaryAs director of the Center for Cellular Immunotherapies, Dr. June leads the translational programme that moves engineered T-cell therapies from the laboratory toward the clinic.
CAR-T Evaluation Pathway (Institutional)
Second OpinionPenn Medicine's Abramson Cancer Center cellular therapy team assesses CAR-T suitability for relapsed or refractory blood cancers. CancerFax can help organise the records needed for this review.
Research & Publications
Landmark cellular immunotherapy research and recognition
A fuller list of Dr. June's publications and honours is available through Penn Medicine and the June Lab.
Education & Training
Dr. June trained at the United States Naval Academy and Baylor College of Medicine, with graduate and post-doctoral training in immunology and transplantation biology.
Clinical Experience
Dr. June has spent more than four decades as a physician-scientist and is one of the defining figures in the development of CAR-T cell therapy.
Languages & International
Dr. June works and consults in English.
CancerFax can coordinate professional medical interpreter support for international patients seeking guidance on CAR-T cell therapy.
CancerFax can coordinate professional medical interpreter support for international patients when required.
How CancerFax Helps You Access Dr. Carl June
CancerFax is a specialist cancer patient-navigation platform. We help international patients prepare structured medical summaries, assess treatment eligibility, and connect directly with Dr. Carl June's team β with full coordination from initial inquiry to consultation.
Medical Report Review
Free review of your pathology results, imaging, molecular profiling, and treatment history β prepared as a structured clinical summary for Dr. Carl June's team.
Treatment Eligibility Screening
CancerFax screens your case for eligibility for treatments and clinical programmes available through Dr. Carl June before you travel, so you arrive with a clear pathway.
Case Submission
We coordinate direct case submission to Dr. Carl June's department, including all documentation required for clinical review and appointment scheduling.
Appointment & Consultation Coordination
CancerFax manages appointment scheduling with Dr. Carl June's team, confirming availability and aligning timelines with your travel plans.
Travel, Visa & Logistics Support
We prepare visa invitation letters, provide hospital-proximity accommodation guidance, and coordinate airport transfers for international patients.
Follow-Up & Continuity of Care
After your consultation or treatment, CancerFax facilitates communication between Dr. Carl June's team and your home oncologist for seamless post-treatment follow-up.
Frequently Asked Questions About Dr. Carl June
Dr. Carl June is a physician-scientist at the University of Pennsylvania and Penn Medicine who is internationally recognised for pioneering CAR-T cell therapy. His engineered T-cell research helped lead to tisagenlecleucel (Kymriah), the first FDA-approved CAR-T therapy, and he received the 2024 Breakthrough Prize in Life Sciences for this work.
Yes. Work from Dr. June's research programme contributed to the engineered T-cell therapy known as tisagenlecleucel, later approved as Kymriah for certain leukaemia and lymphoma indications.
Kymriah (tisagenlecleucel) is approved for certain B-cell acute lymphoblastic leukaemia and B-cell non-Hodgkin lymphoma settings, including some relapsed or refractory cases. The exact use depends on the diagnosis, age, prior treatment, disease status, and the treating centre's criteria.
No. CAR-T eligibility is highly specific. It depends on the cancer type, prior therapies, current disease status, organ function, infection risk, product availability, and the treating centre's criteria. Final eligibility is determined by a qualified CAR-T centre or trial investigator, not by a website profile.
Dr. June is a physician-scientist, and Penn Medicine's public profile states that he does not have privileges to treat patients in the hospital. CAR-T evaluation and treatment at Penn Medicine are handled by the Abramson Cancer Center cellular therapy team. CancerFax can help organise your reports and support referral navigation, but direct physician availability and treatment eligibility must be confirmed by the institution.
CancerFax can review your medical reports and treatment history, prepare a structured case summary for specialist review, identify whether the case may require CAR-T centre evaluation, second opinion, or clinical trial screening, and coordinate communication with the appropriate hospital or trial team. Final treatment decisions are always made by the qualified treating team.
Connect with Carl June Today
Share your medical reports for a free preliminary review. Our patient coordinators will help you understand your options and arrange a direct consultation.
Medical Disclaimer: Information on this page is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making any medical decisions.